Dendreon expects $529.2 million from senior notes, as it advances plans for EU
This article was originally published in Scrip
Executive Summary
US biotech Dendreon has said that it expects to raise net proceeds of $529.2 million from its sale of senior notes due 2016. JP Morgan Healthcare is the underwriter.